Note: All changes are versus the prior-year period unless otherwise stated
"We are very satisfied with the performance in the first nine months of 2020 despite the negative impacts from COVID-19," remarked CEO Lars Fruergaard Jørgensen, adding "more patients use our GLP-1 treatments, and our diabetes market leadership continues to expand."
Novo Nordisk reaffirmed that as announced earlier in October, it expects both sales and operating profit for 2020 to grow between 5% and 8% on a CER basis.
Fruergaard said that while fewer patients with diabetes had initiated treatment this year, a "gradual recovery" had taken place during the third quarter. "We assume that will continue into the fourth quarter, but the guidance range reflects that we live in very volatile times. We don't know how the winter season will evolve," the executive noted.
To read more Top Story articles, click here.